Table 3.
Differences between clopidogrel antiplatelet modification group and no modification group
| ITT | Modification group (n = 39) | No modification group (n = 167) | P value |
|---|---|---|---|
| Age | 59.82 ± 12.38 | 61.57 ± 11.29 | 0.395 |
| Male (%) | 31 (79.49) | 130 (77.84) | 0.823 |
| TIA (%) | 2 (5.13) | 4 (2.40) | 0.318 |
| Hypertension (%) | 31 (79.49) | 118 (70.67) | 0.267 |
| Diabetes (%) | 16 (41.03) | 73 (43.71) | 0.760 |
| Smoking (%) | 15 (38.46) | 80 (47.90) | 0.287 |
| Previous stroke (%) | 10 (25.64) | 46 (27.54) | 0.809 |
| CHD (%) | 5 (12.82) | 20 (11.98) | 0.988 |
| Intracranial artery stenosis (%) | 25 (64.10) | 124 (74.25) | 0.211 |
| Extracranial artery stenosis (%) | 2 (5.13) | 25 (14.97) | 0.119 |
| Severe cerebral arterial stenosis (%) | 16 (41.03) | 36 (21.56) | 0.012* |
| CCB (%) | 20 (51.28) | 70 (41.92) | 0.434 |
| PPI (%) | 1 (2.56) | 0 | 0.044* |
| β-blocker (%) | 4 (10.26) | 16 (9.58) | 0.990 |
| ACEI/ARB (%) | 11 (28.21) | 44 (26.35) | 0.980 |
| PRU (%) | 187.74 ± 78.85 | 164.69 ± 61.92 | 0.051 |
| Mono clopidogrel (%) | 7 (17.95) | 64 (38.32) | 0.016* |
| Clopidogrel and aspirin (%) | 32 (82.05) | 103 (61.68) | |
| Loss to follow-up (%) | 3 (7.69) | 22 (13.17) | 0.66 |
| PPS | Modification group (n = 36) | No modification group (n = 145) | P value |
|---|---|---|---|
| Age | 60.89 ± 11.35 | 60.78 ± 10.79 | 0.957 |
| Male (%) | 29 (80.56) | 113 (77.93) | 0.732 |
| TIA (%) | 2 (5.56) | 2 (1.38) | 0.127 |
| Hypertension (%) | 28 (77.78) | 102 (70.34) | 0.375 |
| Diabetes (%) | 14 (38.89) | 63 (43.45) | 0.620 |
| Smoking (%) | 15 (41.67) | 73 (50.34) | 0.351 |
| CHD (%) | 5 (13.89) | 20 (13.79) | 0.988 |
| Previous stroke (%) | 10 (27.78) | 38 (26.21) | 0.848 |
| Intracranial artery stenosis (%) | 23 (63.89) | 108 (74.48) | 0.203 |
| Extracranial artery stenosis (%) | 2 (5.56) | 22 (15.17) | 0.128 |
| Severe cerebral arterial stenosis (%) | 16 (41.67) | 36 (24.83) | < 0.001* |
| No surgery for stenosis (%) | 14/16 (87.5) | 9/36 (25) | < 0.001* |
| CCB (%) | 20 (55.56) | 70 (48.28) | 0.434 |
| PPI (%) | 1 (2.78) | 0 | 0.044* |
| β-blocker (%) | 4 (11.11) | 16 (11.03) | 0.990 |
| ACEI/ARB (%) | 11 (30.56) | 44 (30.34) | 0.980 |
| In-hospital NIHSS (%) | 2.86 ± 2.47 | 2.29 ± 2.41 | 0.206 |
| Discharge NIHSS (%) | 1.31 ± 1.47 | 1.46 ± 1.56 | 0.604 |
| PRU (%) | 184.23 ± 80.25 | 160.74 ± 59.94 | 0.054 |
| Mono clopidogrel (%) | 7 (19.44) | 51 (35.17) | 0.070 |
| Clopidogrel and aspirin (%) | 29 (80.56) | 94 (64.83) | |
| Adherence (%) | 1 (2.78) | 15 (10.34) | 0.152 |
| Primary endpoint (%) | 5 (13.89) | 12 (8.28) | 0.301 |
| Secondary endpoint (%) | 1 (2.78) | 0 | 0.628 |